Distributor inventory | Tablet
Glimepiride 2 mg + Metformin hydrochloride 500 mg + Voglibose 0.2 mg (tablet)
Type 2 diabetes mellitus (adult) when blood sugar is not adequately controlled with diet/exercise and/or single or dual oral antidiabetic therapy; helps control post‑meal and fasting blood glucose.
Glimepiride (sulfonylurea) increases insulin release from the pancreas. Metformin reduces glucose production in the liver and improves insulin sensitivity. Voglibose (alpha‑glucosidase inhibitor) delays carbohydrate absorption in the intestine, reducing post‑meal sugar spikes.
Oral tablet. Take exactly as prescribed, usually once daily with the first main meal (or as advised). Swallow whole with water; do not skip meals to reduce risk of low blood sugar. Regularly monitor blood glucose and follow diet/exercise plan.
Common side effects of GLIMEVEL-MV2 TAB may include:
Risk of hypoglycaemia (more likely with missed meals, heavy exercise, alcohol, elderly, kidney/liver impairment); carry glucose source. Metformin may rarely cause lactic acidosis—seek urgent care for rapid breathing, severe weakness, abdominal pain, or unusual sleepiness. Use caution/avoid in severe renal impairment, severe liver disease, dehydration, severe infection, shock, or hypoxia. Stop temporarily before/after iodinated contrast procedures or major surgery as advised. Monitor kidney function, liver function, and HbA1c periodically.
